Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings Release and Conference Call

  Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings   Release and Conference Call  Business Wire  MORRISVILLE, N.C. -- January 29, 2013  Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter and full year 2012 financial results on Wednesday, March 6, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.  On Thursday, March 7, 2013, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:  Participant dial-in:  +1 877 677 9122 (U.S./Canada)                       +1 708 290 1401 (International) Conference ID:         94872897  All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay.  About Furiex Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, three products on the market and a fourth approved in the United States but not yet launched. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.  Contact:  Furiex Pharmaceuticals Media/Analysts/Investors: Sailash Patel, 919.456.7814 sailash.patel@furiex.com